8-K: Athira Pharma Implements 10-for-1 Reverse Stock Split

Athira Pharma will effect a 10-for-1 reverse stock split to meet Nasdaq listing requirements and enhance marketability, effective September 17, 2025.

Summary

• Athira Pharma, Inc. will effect a 10-for-1 reverse stock split of its common stock, effective at 5:00 p.m. Eastern Time on September 17, 2025.
• Common stock is expected to begin trading on a post-split basis on The Nasdaq Capital Market as of the open of trading on September 18, 2025, under the existing ticker symbol ATHA.
• The total number of authorized shares of common stock will be reduced from 900,000,000 to 90,000,000.
• The total number of authorized shares of capital stock will be reduced from 1,000,000,000 to 190,000,000, with preferred stock remaining at 100,000,000 shares.
• The par value per share of common stock will remain unchanged at $0.0001.
• Fractional shares resulting from the split will be paid out in cash.
• Proportional adjustments will be made to outstanding options, restricted stock units, and equity incentive plans.
• The primary purpose of the reverse stock split is to increase the price per share to comply with Nasdaq's $1.00 minimum bid price requirement for continued listing.

Sentiment

Score: 3

Explanation: While intended to maintain Nasdaq listing and improve marketability, a reverse stock split typically signals prior stock underperformance and carries risks that its objectives may not be fully achieved. It addresses a compliance issue rather than reflecting positive operational developments.

Positives

• Aims to increase the price per share to regain compliance with Nasdaq's minimum bid price requirement, preventing potential delisting.
• Intends to improve the marketability and liquidity of the common stock.
• Seeks to appeal to a broader range of investors and generate greater investor interest in the company.

Negatives

• A reverse stock split is typically a reactive measure to a declining stock price, indicating past underperformance.
• There is a risk that the reverse stock split may not successfully increase the price per share to maintain Nasdaq listing compliance.
• The split may not improve the marketability and liquidity of the common stock as intended.
• There is a risk that the split may fail to generate greater investor interest in the company.

Risks

• The reverse stock split may not increase the price per share of the common stock sufficiently to allow the company to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq.
• The reverse stock split may not improve the marketability and liquidity of the company's common stock.
• The reverse stock split may fail to generate greater investor interest in the company.

Future Outlook

The company anticipates that the reverse stock split will increase its share price to meet Nasdaq's minimum bid price requirement, potentially improving marketability and liquidity, and attracting broader investor interest. However, the company also acknowledges the risk that these intended effects may not materialize.

Management Comments

• The Board of Directors determined to effect the Reverse Stock Split at a ratio of 10-for-1 following stockholder approval at the Annual Meeting.

Industry Context

Reverse stock splits are a common corporate action for companies, particularly in the biotechnology sector, whose stock prices have fallen below exchange minimums. This action is typically taken to maintain listing compliance on major exchanges like Nasdaq, which have minimum bid price requirements to ensure a certain level of market stability and investor confidence.

Corporate Governance

Stakeholder Impact

• Shareholders: The number of shares held will be reduced by a factor of ten, but the proportional ownership and initial aggregate value should remain the same. Fractional shares will be cashed out. The action aims to improve the stock's marketability and liquidity, potentially benefiting shareholders, but also carries the risk that these goals may not be achieved.
• Nasdaq: The action is intended to bring the company into compliance with Nasdaq's minimum bid price requirement, maintaining its listing.

Next Steps

• The company's common stock will begin trading on a split-adjusted basis on Nasdaq on September 18, 2025.
• Computershare Inc., the transfer agent, will process the exchange of pre-split shares for post-split shares and handle cash payments for fractional shares.

Key Dates

Recommendation

The reverse stock split is a necessary corporate action to maintain Nasdaq listing compliance, addressing a critical issue. While it aims to improve marketability and attract broader investor interest, it does not fundamentally alter the company's operational performance or prospects. Investors should hold to observe the effectiveness of the split in stabilizing the share price and to assess future business developments.

Keywords

Athira Pharma, ATHA, Reverse Stock Split, Nasdaq Listing, Biopharmaceutical, Neurodegeneration, Corporate Action, Stock Market